Lyceum World

What Lyceum World does

Lyceum World, operated by Lyceum Life Sciences Pvt Ltd, is an India-based specialty branded pharmaceutical company founded in 2019 and headquartered in Ahmedabad. The company markets approximately 90+ branded pharmaceutical formulations across six therapeutic areas — neurology/psychiatry, pain management, cardiovascular disease, diabetes, gastrointestinal disorders, and antibiotics — with supplementary products in osteoporosis, renal, anti-allergy, and women's health. Differentiated proprietary formulations include Encefalon (Resveratrol-based blood-brain barrier protection), Populas (Palmitoylethanolamide + probiotics for chronic and neuropathic pain), and Neotide-Plus (nucleotide-based nerve repair targeting Schwann cell activation). Lyceum positions itself on evidence-based combination products for chronic illness management.

The company operates an asset-light business model, outsourcing manufacturing to premium WHO/GMP-certified Indian contract manufacturers — most notably through a strategic alliance with Rebase Lifescience Pvt. Ltd., which produces softgel capsules, tablets (including effervescent and extended-release), hard gelatin capsules, oral powders, and jellies. Lyceum does not own manufacturing facilities. Revenue is generated through B2B pharmaceutical product sales via a multi-tier distribution network spanning CFAs (Carrying and Forwarding Agents), Super Distributors, and Distributors across India, with products ultimately dispensed through retail pharmacies and (for select SKUs like Populas) online platforms such as 1mg.com.

Commercial operations are supported by a tiered field sales organization covering BDE, ABM, ZBM, and RBM roles across CNS, CND, Ortho, and Gastro business units, complemented by healthcare-professional training programs (Prayas) and CSR initiatives (Lyceum Foundation). The company serves healthcare providers (neurologists, psychiatrists, cardiologists, orthopedists, general physicians) and indirectly their patients. Pricing is quote-based through distribution partners and is not publicly disclosed. Lyceum holds GMP and ISO-aligned quality commitments, has received multiple industry awards (Atal Achievement Awards 2024, India MSME Awards 2023, ICONS OF ASIA Award 2022), and is founder/management-owned with no disclosed external institutional funding.

Name

Lyceum World

Legal name

Lyceum Life Sciences Pvt Ltd

Website

https://lyceumworld.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Lyceum World is an Indian specialty pharmaceutical company that markets 90+ branded formulations across six therapeutic areas (neurology, pain, cardiovascular, diabetes, GI, antibiotics) through a pan-India CFA/distributor network and outsourced manufacturing partners.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Specialty pharmaceuticals
• Branded generic drugs
• Chronic disease management
• Pharmaceutical distribution
• Neurology medications

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from marketing and selling branded pharmaceutical formulations across multiple therapeutic areas including CNS, pain management, GI disorders, diabetes, and antibiotics through a distribution network.
2. Business Development Partnerships: Partnering with pharmaceutical manufacturers to bring quality medicines to market. Strategic alliances with manufacturing partners who are premium quality IPM (Indian Pharmaceutical Market) players.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Lyceum World markets and distributes a portfolio of approximately 90+ branded specialty pharmaceutical formulations across therapeutic areas including CNS/Neurology (epilepsy, stroke, Alzheimer's, migraine), chronic and neuropathic pain, cardiovascular, diabetes, GI disorders, antibiotics, osteoporosis, and supplements. Products are developed in-house and manufactured through outsourced WHO/GMP-certified manufacturing partners, then sold pan-India under Lyceum's proprietary brands through a multi-tier CFA/Super Distributor/Distributor network.

Product overview

Lyceum World is a specialty branded pharmaceutical company focused on delivering quality, affordable, and reliable medicines to help patients 'Live without Limits.' The company operates a diverse portfolio of branded pharmaceutical products across multiple therapeutic categories, including neurological products (Encefalon for BBB protection, Populas and Neotide-Plus for neuropathic pain), psychiatric products, cardiovascular products, metabolic/diabetes products, gastrointestinal products, antibiotics, musculoskeletal products, anti-allergy treatments, renal disorder products, women's health products, and supplements. The portfolio includes approximately 90+ branded pharmaceutical products covering areas such as Epilepsy, Stroke, Pain, GERD, Antibiotics, Antioxidants, and CNS disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Encefalon Neurological supplement containing Resveratrol, omega-3 fatty acids, vitamin D3, B-vitamins, and magnesium that targets multiple pathways implicated in neurodegeneration and helps protect blood-brain barrier (BBB) integrity.
• Populas Chronic and neuropathic pain relief tablets containing Palmitoylethanolamide (PEA) 600mg and probiotics 30mg, addressing mast cell activation and providing anti-inflammatory, analgesic, and neuroprotective properties.
• Populas Gold Enhanced pain management supplement combining Palmitoylethanolamide (PEA), L-Tryptophan, and probiotics to address both chronic pain and associated anxiety/depression through a holistic wellness approach.
• Neotide-Plus Clinically proven neuropathic pain relief capsules utilizing nucleotide technology for nerve repair, targeting Schwann cell activation, neurite sprouting support, and pain signal reduction. Indicated for diabetic neuropathy, post-herpetic neuralgia, peripheral nerve injuries, chemotherapy-induced neuropathy, and nerve compression syndromes.
• Hipocam 450mg tablets for hippocampal dysfunction associated with debilitating cognitive disorders.
• Cereceum Branded pharmaceutical product indicated for stroke management.
• Centilin Branded pharmaceutical product indicated for stroke management.
• Centilin-Plus Branded pharmaceutical product indicated for stroke management.
• Brivafix Branded pharmaceutical product indicated for epilepsy management.
• Lacofix Branded pharmaceutical product indicated for epilepsy management.
• Levifix (including Levifix Inj) Branded pharmaceutical product indicated for epilepsy management, also available in injectable form (Levifix Inj).
• Valdron Branded pharmaceutical product indicated for epilepsy management.
• Ramlift Branded pharmaceutical product indicated for Alzheimer's and dementia management.
• Miramax Branded pharmaceutical product indicated for Alzheimer's and dementia management.
• Aurafree Branded pharmaceutical product indicated for migraine management.
• Lycenol-Plus Branded pharmaceutical product indicated for migraine management.
• Sumalgia Branded pharmaceutical product indicated for migraine management.
• Lycetop Branded pharmaceutical product indicated for migraine management.
• OxeBrain Branded pharmaceutical product indicated for neurodegenerative and psychiatric disorder management.
• Vicoten Branded pharmaceutical product indicated for vertigo management.
• AlfaDep Branded pharmaceutical product indicated for anxiety and depression management.
• Praxium CR Branded pharmaceutical product indicated for anxiety and depression management.
• Lycedep-Plus Branded pharmaceutical product indicated for anxiety and depression management.
• Duloxium Branded pharmaceutical product indicated for anxiety and depression management.
• Voxium Branded pharmaceutical product indicated for anxiety and depression management.
• Trankwil Oral Spray Branded pharmaceutical oral spray product indicated for sleep management.
• Benfoceum Branded pharmaceutical product indicated for pain management.
• Lycegalin-NT Branded pharmaceutical product indicated for pain management.
• Lycegalin Duo Branded pharmaceutical product indicated for pain management.
• Lycegab-NT Branded pharmaceutical product indicated for pain management.
• Lycefenac-TH Branded pharmaceutical product indicated for pain management.
• Lycebac Branded pharmaceutical product indicated for pain management.
• Lycetol Branded pharmaceutical product indicated for pain management.
• Lycecort Branded pharmaceutical product indicated for pain management.
• Samiday Branded pharmaceutical product indicated for pain management.
• Defragwell Branded pharmaceutical product indicated for cardiovascular disease management.
• Lycedepin Branded pharmaceutical product indicated for cardiovascular disease management.
• Telinam Branded pharmaceutical product indicated for cardiovascular disease management.
• Teliclo Plus Branded pharmaceutical product indicated for cardiovascular disease management.
• Lyceryl Plus Branded pharmaceutical product indicated for diabetes management.
• Vlamidir Branded pharmaceutical product indicated for diabetes management.
• DapaCeum Branded pharmaceutical product indicated for diabetes management.
• Russela Gold Branded pharmaceutical product indicated for lipid regulation and anti-coagulation.
• Russela Branded pharmaceutical product indicated for lipid regulation and anti-coagulation.
• Dabilant Branded pharmaceutical product indicated for lipid regulation and anti-coagulation.
• Omebac Branded pharmaceutical product indicated for gastrointestinal disorders, available in multiple formulations.
• Papinet Branded pharmaceutical product indicated for gastrointestinal disorders, available in DSR formulation.
• Lycewell Branded pharmaceutical product indicated for gastrointestinal disorders.
• ResLiva Branded pharmaceutical product indicated for gastrointestinal disorders.
• Glutaceum Branded pharmaceutical product indicated for gastrointestinal disorders.
• Lycefoxim Branded antibiotic pharmaceutical product.
• Lyceclav 625 Branded antibiotic pharmaceutical product in 625mg formulation.
• TazoCeum-P Branded antibiotic pharmaceutical product.
• Meronez Branded antibiotic pharmaceutical product.
• Redistep Branded pharmaceutical product indicated for osteoporosis management.
• Dceum3 Branded pharmaceutical product indicated for osteoporosis management.
• Elceum Branded pharmaceutical product indicated for osteoporosis management.
• Monteceum-LC Branded pharmaceutical product indicated for anti-allergy treatment.
• Esketo Branded pharmaceutical product indicated for renal disorder management.
• Febuceum Branded pharmaceutical product indicated for renal disorder management.
• Sobica Branded pharmaceutical product indicated for renal disorder management.
• Encircle Branded pharmaceutical product indicated for PCOD and iron deficiency management.
• Feritol Branded pharmaceutical product indicated for PCOD and iron deficiency management.
• Alfibo Branded pharmaceutical supplement product.
• Autofegi Branded pharmaceutical supplement product.
• Zadicta Branded pharmaceutical supplement product.
• ViuNex Branded pharmaceutical product indicated for ocular abnormalities.

Quantifiable outcome

• Achieved significant milestones within 3 years of operation
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Rebase Lifescience Pvt. LtdcoreStrategic or Co-development PartnerStrategic manufacturing alliance with Rebase Lifescience Pvt. Ltd, which has state-of-art infrastructure certified by WHO and GMP. Rebase manufactures Softgel capsules (Veg & Gelatin), Tablets (Effervescent, Extended release), Hard Gelatin Capsules, Oral Powders & Jelly. Lyceum has strategic alliance with Rebase for quality brands and timely delivery.
• IANCONminorOthersParticipation in IANCON (International Conference) as an exhibitor to showcase products and network with healthcare professionals.
• ANEICONminorOthersParticipation in ANEICON medical conference for neuroscience education and product showcase.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Glenmark Pharmaceuticals: Indian-headquartered pharma with branded specialty formulations across CNS, dermatology, cardiovascular and respiratory therapy — overlaps Lyceum's CNS and chronic-therapy footprint but at materially larger scale.
• Alkem Laboratories: Large Indian pharma with branded specialty formulations across multiple chronic therapy categories including CNS, pain, GI and anti-infectives overlapping with Lyceum's portfolio.
• Torrent Pharmaceuticals: Large Indian pharma with a chronic-care specialty focus (cardio, CNS, diabetology) — broader portfolio and deeper prescriber relationships than Lyceum across overlapping therapy areas.
• Mankind Pharma: One of the largest Indian pharma companies with a broad branded-generics portfolio that overlaps CNS, pain and chronic therapy areas served by Lyceum; significantly larger field force and brand budgets.

Direct peers

• Ajanta Pharma: Mid-sized Indian pharma with branded specialty formulations across CNS, pain, cardiology and anti-infectives; comparable to Lyceum in chronic-therapy branded marketing via field force distribution.
• Eris Lifesciences: Indian specialty pharma focused on chronic-disease branded formulations (cardio-metabolic, CNS, women's health) — closely mirrors Lyceum's branded specialty chronic-therapy model and pan-India distribution playbook.
• Centaur Pharmaceuticals: Indian specialty pharma with branded formulations across CNS, pain and respiratory; operates through similar pan-India distributor-led commercialization approach.
• Unichem Laboratories: Indian branded specialty pharma with branded formulations in CNS, GI and pain; operates a similar B2B distributor model targeting physicians in chronic therapy areas.
• Micro Labs: Indian pharma with branded specialty formulations across CNS, cardiovascular, anti-infectives and pain — directly comparable branded-generics chronic-therapy portfolio.
• IPCA Laboratories: Indian pharma with branded specialty focus on pain management, anti-infectives and chronic therapy — competing head-to-head with Lyceum in neurology and pain therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/LyceumWorld

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyceum World